Skip to main content

Table 3 Summary of the cited references on treating atypical fracture with teriparatide

From: Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment

Reference Case No. Sex Bisphosphonates exposure Surgery or not Duration of teriparitide Result summary
Huang et al. 2012 [16] 1 F 3 yr No 9 mo After 1 mo, pain and tenderness improved
After 9 mo, symptoms disappeared
After 15 mo, fracture line completely healed
Gomberg et al. 2011 [17] 1 (bilateral) F 13 yr No 21 mo After 6 mo, decreased edema at the fracture sites with cortical bridging on MRI.
After 16 mo, pain-free and return to work After 21 mo, complete healing on MRI.
Carvalho et al. 2011 [18] 1 F 4 yr IM nail 3 mo After 1 mo, closure of the right femur fracture
After 3 mo, sβ-CTX and serum osteocalcin increased by 22 and 300%, respectively
Tsuchie et al. 2015 [19] 2 (1 bilateral) Both F 4/6 yr Locking plate 12 mo After 3 and 6 mo, fracture line almost healed.
After 3 and 2 yr, no thigh pain, respectively.
Mastaglia et al. 2016 [20] 1 F 7+ yr IM nail 3 mo After 1 mo, significant pain relief and walk without support
After 3 mo, fracture healed on CT
Chiang et al. 2013 [21] 14 13F, 1M 4-10 yr 3 patients 6 mo Five treated with teriparatide, 2-3 fold increase in bone remodeling markers and fracture healing.
Of 9 patients without teriparatide, 3 had prophylactic surgery. All remaining 6 had nonunion.
Saleh et al. 2012 [22] 10 (4 bilateral) All F 10±5 yr IM nail in 7 8 patients for 24 mo Five fractures without radiolucent fracture line treated conservatively with protection and teriparatide.
Of 9 fractures with a radiolucent fracture line, 2 were successfully treated with teriparatide. Six treated by surgery and teriparatide for 3 mo. One treated only by surgery.
  1. IM, intramedullary, yr, year; mo, month; sβ-CTX, serum β-carboxyterminal telopeptide; MRI, magnetic resonance imaging; CT, computed tomography